DC-CIK细胞免疫增强的功效 化疗对实体癌：一个Meta分析 中国患者随机对照试验.pdf

Lan et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2015 16(9):743-756 743 Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients * Xiao-peng LAN, You-gen CHEN, Zheng W ANG, Chuan-wei YUAN, Gang-gang WANG, Guo-liang LU, Shao-wei MAO, Xun-bo JIN, Qing-hua XIA ??(Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250014, China ) E-mail: xqhgege@ Received Dec. 31, 2014; Revision accepted Ma y 5, 2015; Crosschecked Aug. 10, 2015 Abstract: Objective: Professional ant igen-presenting dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, hav e shown clinical benefits and potentia l to e chemotherapeutic re- sistance. To evaluate whether DC-CIK ce ll-based therapy improves the clinical efficacy of chemotherapy, we reviewed the literature on DC-CIK cells and meta-a nalyzed randomized controlled trials (RCTs). Methods: We searched several databases and selected studies using predefined criteria. RCTs that applied c hemotherapy with and without DC-CIK cells separately in two groups were included. Odds ratio (OR) and mean difference (MD) were reported to measure the pooled effect. Results: Twelve reported RCTs (826 patient s), which were all performed on Chinese patients, were included. Combination therapy exhibited better data than c hemotherapy: 1-year overall survival (OS) (OR=, P<), 2-year OS (OR=, P<), 3-year OS (OR=, P<), 1-year disease-free survival (DFS) (OR=, P<), 3-year DFS (OR=, P<), objective response rate (ORR) (OR=, P<), and disease control rate (DCR) (OR=, P<). Moreover, the levels of CD3 + T-lymphocytes (MD= ? , P<) and CD4 + T-lymphocytes (MD= ? , P<) of bination group were high er. Conclusions: Immunotherapy of DC-CIK cells may enhance the efficacy o